This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baca, L. Articles by Martinelli, L. Search for Related Content PubMed PubMed Citation Articles by Baca, L. Articles by Martinelli, L.

NEUROLOGY 1990;40:1797
© 1990 American Academy of Neurology

Neuroleptic malignant syndrome

A unique association with a tricyclic antidepressant Loretta Baca, MD, and and Lawrence Martinelli, MD

Department of Medicine, Saint Joseph Hospital, Denver, CO.

We report the 1st case of neuroleptic malignant syndrome occurring in a patient receiving desipramine, a tricyclic antidepressant, with no exposure to neuroleptics. Our case suggests that this syndrome may be caused by a central imbalance between norepinephrine and dopamine, and not by dopamine depletion alone.

Address correspondence and reprint requests to Dr. Loretta Baca, Associate Director, Department of Medicine, Saint Joseph Hospital, 1835 Franklin Street, Denver, CO 80218.

Received November 20, 1989. Accepted for publication in final form April 12, 1990.

This article has been cited by other articles:

				M Chandran and M El-Shazly Catatonia, neuroleptics and brain damage - a case report J Psychopharmacol, March 1, 2009; 23(2): 223 - 226. [Abstract] [PDF]

				S. R. White Acute Dystonic Reaction and the Neuroleptic Malignant Syndrome Journal of Pharmacy Practice, June 1, 2005; 18(3): 175 - 187. [Abstract] [PDF]

				L. A. Squires, A. M. Neumeyer, J. Bloomberg, and K. S. Krishnamoorthy Hyperpyrexia in an Adolescent on Desipramine Treatment Clinical Pediatrics, October 1, 1992; 31(10): 635 - 636. [PDF]